333361-51-6

4-Bromo-1-chloro-2-[(4-methoxyphenyl)methyl]benzene is an intermediate in synthesizing Dapagliflozin-D5 (D185372), a labelled analogue of Dapagliflozin (D185370), which is a selective sodium-glucose cotransporter-2 inhibitor that reduces renal glucose reabsorption and is used to treat patients with type 2 diabetes.